Newsfeeds - Spark Newswire

1 minute read

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Today, 1:04 PM

Sarepta Therapeutics Inc (NASDAQ:SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. …

RHHBF

3 minute read

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer’s Drug Due In January, FDA Reviews Roche’s Lymphoma Candidate, Rare Pediatric Tag For Kazia’s Pediatric Brain Cancer Candidate

By Vandana Singh

Today, 1:04 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AMTI

1 minute read

Analyst Ratings

Where Sarepta Therapeutics Stands With Analysts

By Benzinga Insights

Today, 1:04 PM

Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter:

SRPT

1 minute read

Cantor Fitzgerald Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $128

By Benzinga Newsdesk

Today, 1:04 PM

Cantor Fitzgerald analyst Kristen Kluska maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $140 to $128.

SRPT

1 minute read

Sarepta Therapeutics’ Shares Plummet Following FDA’s Clinical Hold On MOMENTUM Study

By Ragothaman Srinivasan

Today, 1:04 PM

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.

SRPT

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

Today, 1:04 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

AMGN

1 minute read

Goldman Sachs Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $155

By Benzinga Newsdesk

Today, 1:04 PM

Goldman Sachs maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $181 to $155.

SRPT

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 1:04 PM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

1 minute read

Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Lowers Price Target to $77

By Benzinga Newsdesk

Today, 1:04 PM

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and lowers the price target from $80 to $77.

SRPT

1 minute read

Analyst Ratings

Where Sarepta Therapeutics Stands With Analysts

By Benzinga Insights

Today, 1:04 PM

Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

SRPT